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SUMMARY
Purpose: Lennox-Gastaut syndrome (LGS) is a devastating childhood-onset epilepsy
syndrome. The cause is unknown in 25% of cases. Little has been described about the
specific clinical or electroencephalography (EEG) features of LGS of unknown or
genetic cause (LGSu). The Epilepsy Phenome/Genome Project (EPGP) aims to charac-
terize LGSu by phenotypic analysis of patients with LGSu and their parents.
Methods: One hundred thirty-five patients with LGS with no known etiology and their
parents were enrolled from 19 EPGP centers in the United States and Australia. Clini-
cal data from medical records, standardized questionnaires, imaging, and EEG were
collected with use of online informatics systems developed for EPGP.
Key Findings: LGSu in the EPGP cohort had a broad range of onset of epilepsy from 1
to 13 years, was male predominant (p < 0.0002), and was associated with normal
development prior to seizure onset in 59.2% of patients. Despite the diagnosis, almost
half of the adult patients with LGSu completed secondary school. Parents were cogni-
tively normal. All subjects had EEG recordings with generalized epileptiform abnor-
malities with a spike wave frequency range of 1–5 Hz (median 2 Hz), whereas 8.1% of
subjects had EEG studies with a normal posterior dominant rhythm. Almost 12% of
patients evolved fromWest syndrome.
Significance: LGSu has distinctive characteristics including a broad age range of onset,
male predominance, and often normal development prior to the onset of seizures.
Cognitive achievements such as completion of secondary school were possible in half
of adult patients. Our phenotypic description of LGSu coupledwith future genetic stud-
ies will advance our understanding of this epilepsy syndrome.
KEY WORDS: Lennox-Gastaut, Unknown, Slow spike wave, Phenotype, Epilepsy,
Epilepsy Phenome/Genome Project.
“In children with primary LGS, … the tragedy of a
vicious seizure disorder or an “epileptic encephalopathy”
gradually impairing a hitherto healthy brain, ought to
be averted with great insight into genetic factors…”
(Niedermeyer, 1986).
Lennox-Gastaut syndrome (LGS) is a severe childhood-
onset epilepsy associated with multiple seizure types, char-
acteristic electroencephalography (EEG) abnormalities, and
developmental delay, originally described by Lennox in
1949 (Lennox&Davis, 1949; Lennox, 1960) and in the larg-
est series of 100 patients by Gastaut in 1966 (Gastaut et al.,
1966). The term Lennox-Gastaut syndrome was introduced
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in 1969 (Niedermeyer, 1969). Although precise definitions
of LGS vary, most authors agree on childhood-onset refrac-
tory generalized epilepsy with multiple seizure types and
either slow spike wave or generalized paroxysmal fast activ-
ity on EEG (Arzimanoglou et al., 2009). Given the clinical
heterogeneity among cases, multiple pathophysiologic path-
ways or genetic factors likely exist that when elucidated will
define the syndrome in more specific terms. Although rare,
with a prevalence of 0.26 per 1,000 at 10 years (Trevathan
et al., 1997), the disorder is associated with immense physi-
cal, emotional, and social consequences. LGS may evolve
from West syndrome/infantile spasms (IS) in up to 20–30%
of cases (Genton et al., 2000; Crumrine, 2002; Arzimanog-
lou, 2009). The pathogenesis of LGS is poorly understood,
but it may involve a genetic influence on development of the
immature nervous system, particularly during thalamocorti-
cal development, leading to structural or functional brain
pathology (Blume, 2001; Markand, 2003). Approximately
25% of cases (previously referred to as cryptogenic) have an
unknown cause, with underlying genetic factors suspected
but as yet unconfirmed.
Few studies have separated cases of LGS of unknown
cause (LGSu) from cases with known structural or metabolic
etiologies (LGSs). Published series suggest that LGSu has
clinical characteristics distinct from LGSs, including normal
development or mild delay prior to the development of sei-
zures, a later age of onset, a nonlocalizing neurologic exam-
ination, normal brain magnetic resonance imaging (MRI),
and the absence of dysmorphic features. LGSu was less
likely than LGSs to evolve from infantile spasms. Ten
percent to 20% of patients with LGS have normal cogni-
tion, particularly if onset is later in the second decade or
in cases of unknown etiology (Niedermeyer, 1986; Gold-
smith et al., 2000). Outcome was better in cases of
unknown cause, with a later age of onset, and in those
with a normal examination (Oguni et al., 1996; Gold-
smith et al., 2000).
Other LGS variants are reported, such as a “myoclonic
variant” with a less severe phenotype, nocturnal only sei-
zures, and unknown etiology (Chevrie & Aicardi, 1972). A
higher rate of family history of seizures than the general
population is reported in LGSu (Boniver et al., 1987).
Systematic definition of the clinical phenotype of LGSu
is critical to expand our knowledge of this distinctive sub-
group of LGS and to correlate with genetic studies. Avail-
ability of high quality phenotypic data in sufficient quantity
has been the major limiting factor in phenome–genome
association studies. To address this, the Epilepsy Phenome/
Genome Project (EPGP) was formed as a multicenter col-
laborative effort of 27 epilepsy centers in the United States,
Australia, New Zealand, and Argentina, funded by the
National Institute of Neurological Disorders and Stroke
(NINDS), to collect detailed phenotypic and genetic data on
a large number of patients with epilepsy, including LGSu
(The EPGP Collaborative, 2013). The main hypothesis for
the LGSu component of the study is that de novo mutations
are important causes for these patients, given that LGS does
not show transgenerational transmission and most families
do not have sibling recurrence. By collecting comprehen-
sive phenotypic data on these subjects we will be well-posi-
tioned to understand the consequences of the mutations
identified in a future genomic analysis.
Methods
Participants were identified primarily through the EPGP
Clinical Centers by prospective screening of clinic patients,
retrospective medical record reviews, and ongoing educa-
tion of colleagues within the institution and from neighbor-
ing hospitals and practices. There was also an EPGP
National Recruitment Campaign to recruit eligible families
outside of the Clinical Centers through community advo-
cacy groups, the Internet, news articles, advertising, and
other forms of communication with patients and healthcare
professionals (The EPGP Collaborative, 2013).
Detailed standardized phenotypic data were available
from 135 patients with LGSu, and their parents recruited
from 19 centers in the United States and Australia (sites
are listed in the Table S1). The local institutional review
board approved the study at each center. All subjects
were enrolled after eligibility criteria were confirmed and
they (or their parents) provided written informed consent/
assent.
Patients underwent a detailed, structured review of their
history and records to define characteristics of their seizure
history, seizure types, and additional medical conditions. A
diagnostic interview was completed for 50 early patients,
and was subsequently discontinued as sufficient data
became available from medical record review. Clinical data
were anonymized and entered into a secure centralized
online database (Nesbitt et al., 2012). A final diagnosis
form was completed by the local site principal investigator
based on all collected information. A subset of cases was
reviewed independently by two members of a Data Review
Core to ensure data quality and consistency. A representa-
tive EEG was reviewed by a site investigator and an EEG
Core member to assess data quality and EEG inclusion cri-
teria. EEG findings accepted for inclusion were then
reviewed and scored by two EEG Core members for spe-
cific EEG phenotypic features. The EEG source data
included digital EEG files, scanned pages from paper EEG
samples, EEG reports, or clinical notes describing EEG.
Disagreements were resolved by consensus conference
among two or more EEG Core members before the EEG
data set was finalized. Some subjects had more than one
EEG study, and such supplemental EEG findings were
reviewed and scored in similar fashion. Brain MRI were
reviewed by local investigators and an MRI Core member
to exclude a structural lesion. All patients and their parents
contributed blood samples that were processed for DNA
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extraction and creation of immortalized cell lines, and
stored at the NINDS Repository at the Coriell Institute for
Clinical Research, Camden, NJ.
Inclusion/exclusion criteria
Inclusion and exclusion criteria for LGSu are detailed
in Table 1. EEG criteria included EEG background slow-
ing or disorganization of the EEG background for age,
and generalized spike and wave activity of any frequency
or generalized paroxysmal fast activity (GPFA). Our
protocol required that subjects with a clinical diagnosis of
LGS but whose available EEG did not meet our EEG cri-
teria for LGS, would be referred to the EPGP Phenome
Core for further review. However, this scenario did not
occur with any patient in our group. Background slowing
was defined as <8 Hz posterior dominant rhythm in
patients older than 3 years of age and <5 Hz in patients
older than 2 years of age. EEG studies with normal back-
grounds were accepted if the generalized spike and wave
activity was 2.5 Hz or less or if GPFA was present.
Generalized epileptiform abnormalities could be interictal
or ictal. The MRI studies were normal or showed only
mild diffuse atrophy.
Patients with autism spectrum disorder (ASD) or moder-
ate to severe developmental delay prior to the onset of sei-
zures were excluded. Severe delay prior to seizure onset
was defined by ≥50% delay in any area: motor, social, lan-
guage, cognition, or activities of living; or global delay.
Mild delay was defined as isolated delay of <50% of
expected milestones in one area, or <30% of milestones
across more than one area, which can result in normal devel-
opment as a later time point. Details regarding developmen-
tal delay were obtained from parents through an eligibility
interview and by local investigators from records via a stan-
dardized medical abstraction form. Borderline cases were
adjudicated by the EPGP Phenome Core.
Patients with a history of epilepsy in either biologic par-
ent were intentionally excluded to maximize the chance of
finding de novo mutations in patients with LGSu. Hence the
study was not designed to identify pathogenic mechanisms
in LGS with ASD or familial LGS.
Data were analyzed using the SAS or JMP programs
(SAS Institute, Inc., Cary, NC, U.S.A.). Descriptive statis-
tics were calculated for demographic, family history, and
clinical data. Data are presented as means, standard devia-
tions, and ranges for continuous variables, and frequencies
and percents for categorical variables.
Results
Demographics
One hundred thirty-five patients were included in the
analysis. The median age at enrollment was 14 years (range
2–51 years). Sixty-six percent of patients were male and
34% were female (p < 0.0002, compared with 50%
expected). One hundred four (77%) patients were of white/
Caucasian ethnicity, 10 (7.4%) were Hispanic, two were
Asian, four were African American, and one was Native
American/Alaskan. Fourteen patients were of mixed race
with white/Caucasian along with Native American (8), Afri-
can American (3), Asian (2), and Hawaiian (1). One hun-
dred twenty-three patients (91%) were born in the United
States. Eight patients from the Melbourne site were born in
Australia. One patient each was born in Colombia, Canada,
Table 1. Inclusion and exclusion criteria for the
LGSu arm of EPGP
Inclusion criteria
Generalized epilepsy with multiple seizure types
EEG background slowing or disorganization (normal background
accepted if SWS <2.5 Hz or GPFA present)
Generalized spike and wave or generalized paroxysmal fast activity
Normal MRI (or mild diffuse atrophy)
Parental control with no history of epilepsy (febrile or
provoked seizures allowed)
Adequate records
Exclusion criteria
Known genetic syndrome (known balanced translocations and small
interstitial or telomeric deletions/duplications were included)
TORCH infection
Metabolic disease
Premature birth before 32 weeks
Structural MRI lesion
Hypoxic–ischemic encephalopathy
Meningitis/encephalitis
Stroke/intracerebral hemorrhage
Microcephaly <2.5 standard deviations from normal
Significant head trauma
Autism
Moderate to severe developmental delay prior to onset of seizures
EEG, electroencephalography; SWS, slow spike wave; GPFA, generalized
paroxysmal fast activity.
Table 2. Morphology of epileptiform discharges in
LGSu in 71 patients with available digital EEG
Single spike and wave – 39 (54.9%)
1 hertz – 13
2 hertz – 21
3 hertz – 2
4 hertz – 2
5 hertz – 1
Polyspike spike and wave – 16 (22.5%)
1 hertz – 3
2 hertz – 11
3 hertz – 2
GPFA – 9 (12.6%)
12 hertz – 1
13 hertz – 2
18 hertz – 2
20 hertz – 3
25 hertz – 1
Other – 7 (9.8%)
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Germany, and the United Kingdom. Of patients who were
18 years or older (n = 50), 21 were secondary school
graduates (42%) and 2 (4%) had completed some college
but did not graduate. This group had no developmental
delay prior to seizure onset, and no reliance on special
education was reported by parents. Twenty patients (40%)
did not complete high school. In 13 (65%) of this group,
mild developmental delay was documented prior to seizure
onset, and special education was reported by parents. In
seven patients, details of schooling were unknown or not
asked.
Proband clinical characteristics
The median age at first seizure was 1 year (range <1–
13 years). Most patients were diagnosed with LGSu within a
year of seizure onset (93%). Based on medical record review,
33 patients (24.4%) had mild developmental delay before
onset of seizures, whereas 80 (59.2%) had normal develop-
ment. Based on interviews of parents, mild developmental
delay or a learning disability was present in one third of
patients before onset of seizures. In 22 patients (16.2%), it
was unclear from available records if developmental delay
was present before seizure onset. Febrile seizures occurred in
12.5% (17) of cases. Four of these patients had more than one
febrile seizure and five had complex febrile seizures (one
with focal features and four with duration longer than
15 min). An abnormal neurologic examination within
3 months of the first seizure was observed in 12.5% (17)
of cases, including findings such as hypotonia or increased
tone.
Although records of older patients were often difficult to
obtain, we tried to identify whether a genetic or metabolic
workup had been completed and excluded those with posi-
tive results. A genetics consult was obtained in 32 patients
(23.7%) and a metabolic evaluation was conducted in 39
(28.8%), and no abnormalities were identified. A normal
chromosome analysis was documented for 37 probands
(27.4%).
Parental background
The average age of the parents at the time of birth of the
child who developed LGSu was 31 years, with standard
deviation of 5 years (maternal average 30 years, paternal
average 32 years). Nine of the parents (3.3%) had febrile
seizures as infants, most with single seizures, with two par-
ents having two febrile seizures and one with 10. Six (2.2%)
had single afebrile toxic/metabolic seizures in their lifetime.
No parent had epilepsy, as dictated by inclusion/exclusion
criteria. None of the parents had ever been treated with an
antiseizure medication.
Forty-three parents from 41 different families had a fam-
ily history of epilepsy, of which 11 (10 families, 7.4%) had
a family history in a first-degree relative. Three probands
had siblings with epilepsy (2.2%). Most parents were born
in the United States (83.1%) and 80.1% were of white eth-
nicity. Other ethnicities were similar to those reported of the
probands. Most parents had college education (some college
26.9%, completed college 29.5%, and 15.7% graduate
school), and 17.9% completed secondary school. Only 5.6%
had less than a high school education. 82.3% of the parents
were right handed, 10.5% left handed, and 7.1% ambidex-
trous.
Clinical seizure types
The most common seizure types were absence (80%),
atonic (65.1%), generalized tonic–clonic (60%), and tonic
seizures (55.5%). Other seizure types included myoclonic
seizures (55.5%), complex partial seizures (17%), and
unclassifiable nonconvulsive seizures (6.6%); 21.4% had a
history of infantile spasms. Reflex seizures were seen in
seven patients (two with photoconvulsive seizures, and five
with startle, touch, or sound-sensitive seizures). Only three
patients had reported auras, including psychic, autonomic,
somatosensory, sensory, or visual types.
EEG
One hundred sixty-eight inclusion and supplemental
EEG or EEG reports were analyzed for the 135 patients with
LGSu. The mean posterior dominant rhythm (PDR) was
6.7 Hz (standard deviation [SD] 2.2). Eleven subjects
(8.1%) had an age-appropriate PDR. Eighty (59.2%) had a
slow PDR for age or disorganized background. Nine
patients had absence of a PDR and no underlying EEG back-
ground organization (6.6%). For 35 patients (25.9%) there
was insufficient information on waking EEG background.
Generalized epileptiform abnormalities were seen in 100%
of patients, as dictated by inclusion/exclusion criteria. Focal
sharp waves were seen in 67 (49.6%) and focal slowing in
20 patients (15.2%).
Specific EEG phenotypic features could be assessed from
digital EEG data from 71 patients (Table 2). Generalized
single spike and wave complexes were seen in 39 (54.9%)
with a frequency range of 1–5 Hz (median 2 Hz). General-
ized polyspike and wave complexes were seen in 16
(22.5%) with a frequency range of 1–3 Hz (median 2 Hz).
Seven patients had spike wave frequencies on available
EEG ≥3 Hz. GPFA was seen in 9 (12.6%) with frequencies
between 11 and 25 Hz (median 17).
Diagnosis and evolution
A final International League Against Epilepsy (ILAE)
diagnostic code was applied to each patient based on clini-
cal, EEG, and MRI data. A second code could be applied if
one syndrome evolved into another at a later age. Sixteen
patients (11.8%) had West syndrome (2210, 2211, or 2212),
which evolved to LGSu by a median age of 2 years (range
0–9). Two patients had a generalized epilepsy syndrome
that evolved into LGSu. Some patients’ epilepsy evolved
from LGSu to another ILAE syndrome; two evolved to focal
epilepsy, and two to epileptic spasms.
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Discussion
We present the phenotypic characteristics of the largest
series of LGSu published to date. There is little insight into
the pathogenesis and genetic origin of LGSu (Blume, 2001).
The need for improved disease-specific understanding is
crucial to alleviate this devastating childhood epilepsy, as
seizures are invariably refractory to treatment (Ferrie &
Patel, 2009; Hancock & Cross, 2013).
We found a 2:1 male preponderance in our group of
LGSu, which has been previously observed in some mixed
LGSs and LGSu series but not confirmed (Beaumonoir,
1982). Although not a population-based sample, LGSu
could be added to other early life neurologic disorders with
male preponderance affecting brain development including
autism, Attention Deficit/Hyperactivity Disorder (ADHD),
dyslexia, and Tourette syndrome. This suggests that the
vulnerability of the male brain extends to epilepsy in early
life and may reflect a greater susceptibility of the male
brain, possibly due to the initial early life pulse exposure
to testosterone (Baron-Cohen et al., 2011). Alternatively,
it may suggest mutations involving genes on the X
chromosome.
Developmental delay has been a traditional hallmark of
LGS. However, experience from some cohorts has sug-
gested that development may be normal prior to seizure
onset in LGSu (Beaumonoir, 1982). In our group, 59% of
patients had normal development prior to the onset of sei-
zures, although this result was biased by the exclusion of
patients with more severe delay. Development in patients
with LGSu invariably declines over time with continuing
seizures (Niedermeyer, 1986; Crumrine, 2002; Markand,
2003). Despite this, in our group, 46% of adult patients were
high school graduates. Inclusive education programs in
EPGP countries to promote school completion may partly
explain these figures. In addition, we recognize that enroll-
ment bias exists that could have selected patients with
higher cognitive function. What determines eventual cogni-
tive outcome is unclear, and it is unproven whether inter-
ventions such as early and aggressive seizure control can
improve outcomes compared to high mental retardation
rates reported in older series of undifferentiated LGS.
No prior study has evaluated parental characteristics for
probands with LGS. The majority of parents in our group
were cognitively normal, and had attained some college
education. The average parental age was 31 years, and was
similar in other EPGP arms with parental controls. The aver-
age maternal age at birth in the United States is 27.4 years
(Martin et al., 2007). The higher parental age and level of
education in our cohort likely reflects the sociodemographic
and educational background of the enrolled parents rather
than the general population. Prevalence of a history of feb-
rile seizures in the parents was similar to that expected
based on population frequencies (Sillanpaa et al., 2008).
The proportion of parents with a family history of epilepsy
in first-degree relatives (7.4%) was also consistent with
population rates. (Assuming four first-degree relatives at
risk in each family and a lifetime risk of 2% in each relative,
the probability ≥1 relative was affected is [1(1–
0.02)4] = 7.8%). These findings are consistent with an
effect of de novo mutations on risk for LGSu, in patients
selected on the basis of the absence of a parental history of
epilepsy. This was the original hypothesis that led to the
design of this component of EPGP, and which will be tested
through the genetic analysis planned through the Epi4K
Center without Walls (Epi4K, 2012).
LGS patients typically have tonic or atypical absence sei-
zures, but these seizure types were not always present in our
subjects. The incidence of tonic seizures among our subjects
(55.5%) is less than Gastaut’s original estimate in mixed
LGS of 70% (Niedermeyer, 1986). This may be explained
by the delayed appearance of some seizure types, or by the
variable documentation by sleep or video-EEG recordings
available to EPGP investigators. In addition, clinical fea-
tures in LGS are often variable, with the EEG being more
consistent (Camfield, 2011). Despite the conventional asso-
ciation between LGS and tonic seizures, tonic seizures are
not a requirement in the 1989 ILAE criteria for LGS, and
not in expert reviews (Aicardi, 1996). Myoclonic seizures
or other subtle seizure types (such as brief upgaze and alter-
ations in respiration) may be confused with brief tonic sei-
zures. Generalized tonic–clonic seizures were common
(60%), in contrast to Gastaut’s incidence of 15%. It remains
to be seen whether seizure types or clusters of seizure types
correlate phenotypically with specific genetic findings, such
as is likely with the “myoclonic” and “occipital” variants of
LGS.
The classic EEG finding in LGS is the interictal slow
spike and wave pattern first described in 1939 (Gibbs et al.,
1939). The interictal slow spike andwave pattern is typically
2 or 2.5 Hz in frequency (slower than the 3 Hz spike and
wave pattern seen in Genetic [formerly termed “Idiopathic”]
Generalized Epilepsy). In this cohort, although the median
spike and wave frequency was 2 Hz, it varied between 1 and
5 Hz. Such variations including combinations of slow spike
wave, a faster irregular spike wave, and GPFA within the
clinical spectrum of LGS have been described in the litera-
ture (Markand, 1977; Aicardi, 1996).
Although smaller series suggest that LGSu does not
evolve from IS, several of our patients did evolve fromWest
syndrome, although at a lower rate (11.8%) than that
reported for structural/metabolic cases (20–30%) by other
investigators (Genton et al., 2000; Arzimanoglou et al.,
2009). The biologic basis and genetics of this phenomenon
remain to be elucidated; further study of the EPGP cohort
dedicated to infantile spasms may be revealing.
We acknowledge the potential selection bias introduced
into our sample by the selection criteria. The goal of the
LGS arm of EPGP was to exclude participants with struc-
tural/metabolic or known genetic causes to ensure the best
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possible genetic cohort for the analysis of de novo muta-
tions. The exclusion of parents with epilepsy also aided
our search for these genes, but undoubtedly excluded
certain genotypes and phenotypes. In addition, the need
for complete phenotypic information and blood from both
parents could have selected against patients from lower
socioeconomic and racial groups who are limited by
access to care and other sociodemographic factors.
The standardized phenotypic analysis of this large cohort
of patients with LGSu across several centers and countries
demonstrates a spectrum of clinical, EEG, and developmen-
tal characteristics that will define the syndrome of LGS of
unknown cause to a greater level. It is notable that this data
should provide valuable clinical insight into the mutations
or variants identified during the whole exome screening
underway in Epi4K (Epi4K, 2012), thereby furthering our
understanding of the disease.
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